Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + lenvatinib + belzutifan in advanced solid tumors
2023-503905-12-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of pembrolizumab, lenvatinib and belzutifan in hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic adenocarcinoma (PDAC) and 4 more (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants in lead-in phase with at least one dose-limiting toxicity, Number of participants in Arm 1 (triplet) with at least one adverse event and 2 more. Started Oct 2023; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)biliary cancergallbladder cancer
Beyond the preview
Go deeper on 2023-503905-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503905-12-00.